Ep. 254, Chapter 2: Why tRNA? With Michelle Werner

13:03-30:02

Alltrna's tRNA technology offers unprecedented ability to universally restore protein function across diverse disease models, regardless of affected gene, protein, or mutation location. For investors, Werner emphasizes the immense unmet need in genetic diseases, explaining how tRNA's universal approach to common nonsense mutations provides a compelling "reason to believe" backed by preclinical and now in vivo data. She highlights the company’s plan to utilize basket trials, a strategy common in oncology, to simultaneously its therapies simultaneously across multiple rare diseases sharing common mutations —not only optimizing development, but also unlocking value in ultra-rare diseases often overlooked due to small individual patient populations.